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Introduction
The incidence of oral cancer in Indonesia is still 
quite high and annualy increasing (Budhy et al., 2001). 
Oral Squamous Cell Carcinoma (OSCC) is a type of 
cancer that is often found in oral cavity or in head and 
neck (Kumar et al., 2005). The causal factors of this 
disease are considered complex and therefore needs to 
be concerned (Agar and Patel, 2014; Regezi et al., 2016). 
One of the causes is Epstein Bar Virus (EBV) (Higa et al., 
2002; Acharya et al., 2015; Kikuchi et al., 2017). 
EBV belongs to the family of Herpersviridae, 
which has spread throughout most parts of the world 
(Kieff, 1996; Arvin et al., 2007; Kikuchi et al., 2017). 
The viral genome is hidden constantly in cells with strong 
expression of EBV proteins, nuclear antigen complex 
(EBNA), membrane protein latent (LMP-1 and LMP-2) 
and EBV-RNA (EBER) (Budhy, 2005; Xia et al., 2015; 
Kikuchi et al., 2017). The expression of EBV protein then 
will affect the regulatory process of proteins in the cells 
(Sitki-Green et al., 2004). If the presence of EBV disrupts 
the regulatory process contributing to cell cycle control, 
such as the expressions of inactive p53 (p53i), c-myc 
and bcl-2, both cell apoptosis and cell proliferation 
will be disrupted. This situation can cause the cells to 
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transform into malignant ones, known as carcinogenesis 
(Muller and Vousden, 2014).
Carcinogenesis, according to Kumar et al. (2005), 
may occur due to disruption in the mechanisms of 
regulatory genes related to both cell apoptosis and 
cell proliferation, namely p53. p53 gene is a tumor 
suppressor gene that plays a role in the regulation of 
apoptosis when damages occur (Liu et al., 2015; Yoon et 
al., 2015; Muñoz-Fontela et al., 2016). Carcinogenesis, 
however, is not only determined by p53 gene, but also 
influenced by oncogenes. One of the oncogenes is c-myc 
which functions as a transcription factor and is mostly 
associated with cell transformation. As for apoptosis, 
it is influenced not only by bcl-2 gene, but also by p53i 
gene. Thus, the expressions of the proliferation and 
apoptosis of the regulatory molecules can determine 
the level (grade) of carcinogenesis. This study, therefore, 
aimed to determine the molecular grading pattern of OSCC 
infected by Epstein-Barr Virus (EBV), by analyzing at 
the expressions of p53i, c-myc and bcl-2 genes.
 
Materials and Methods
This study was an observational analytic study. 
The protocol of this study was approved by The Ethic 
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Committee of Universitas Airlangga Faculty of Dental 
Medicine No 074/HRECC.FODM/VII/2017. Biopsy of 
27 subjects with OSCC were performed in Intergrated 
Surgery Center Building of RSUD Dr. Soetomo. 
Inform consents were obtained from all of the subjects.
Examination of EBV infection
The biopsy results were immediately put into a 
deep freezer with the temperature of -70oC. EBER were 
identified using in-situ hybridization method. LMP-1 
and EBNA was examined using immunohistochemistry. 
The staining process was conducted using monoclonal 
antibodies of LMP-1 and EBNA-1 from Dako 
(Agilent, Santa Clara, USA) with Avidin Biotin 
Complex technic from Novo Castra Biotin System 
(Leica Biosystems Newcastle Ltd, Newcastle, UK) in 
order to make the staining results stronger and clearer 
due to the amplification. The assessment of microscopic 
staining results was conducted qualitatively by examining 
the intensity of color absorption, as well as quantitatively 
by counting the number of cells manually that positively 
absorb the color. The present of EBER, LMP-1, and 
EBNA-1 considered as OSCCinfected by EBV group, 
while the absent of those proteins considered as 
non-infected group.
Expression of p53i, c-myc, and bcl-2
The expression of p53i, c-myc, and bcl-2 were examined 
using immunohistochemistry in both groups. The staining 
process was conducted using monoclonal antibodies of 
inactive p53i, bcl-2, c-myc from Dako (Agilent, Santa 
Clara, USA) with Avidin Biotin Complex technic from 
Novo Castra Biotin System (Leica Biosystems Newcastle 
Ltd, Newcastle, UK). The assessment of microscopic 
staining results was also conducted qualitatively and 
quantitatively.
Data analysis
The data was analyzed using SPSS version 10 
(SPSS Inc, Massachusetts, USA). Multivariate Analysis of 
Variance (MANOVA) was used to prove the difference of 
the expressions of p53i, c-myc, ad bcl-2, followed by 
analysis of the molecular grading pattern.
Then, Independent T test was performed to analyze 
EBER, LMP-1, EBNA-1, and bcl2 in both infected and 
uninfected OSCC since the data were normally distributed. 
Meanwhile, to analyze p53i and c-myc expressions, 
Mann Whytney test was conducted since the data was not 
normally distributed. Univariate Linear Regression then 
was carried out to reveal the effects of EBER, LMP-1, 
and EBNA-1 on p53i expression.
Results
Based on Table 1, the standard deviation (SD) was 
generally very high. There were significant differences in 
EBER, LMP-1, EBNA-1, and Bcl-2 between the infected 
(n=17) and non-infected groups (n=10). Meanwhile, 
there were no significant differences in p53i expression 
and C-myc between the infected and non-infected 
groups. Next, the regression test was performed to 
analyze the effects of EBER, LMP1, and EBNA-1 
expressions on p53i, c-myc, and bcl-2 expressions. 
Results of the regression test can be seen in Table 2.
Based on the results of the regression test, only 
EBNA-1 expression affected p53i expression. As a result, 
regression equation test was conducted. Results of 
the regression equation test can be seen as follows.
p53i = 9.574 + 1.043 (EBNA-1)
Based on the regression equation above, it may be said 
that an increase of 1.043 EBNA-1 expression can enhance 
p53i expression by a unit of expression. Consequently, to 
Groups
Variables OSCC infected by EBV (n=17) Non-infected OSCC (n=10) p-value
Mean±SD Mean±SD
EBER 28.75±25.79 0.56±1.67 0.004*
LMP-1 17.50±20.49 0.00±0.00 0.014*
EBNA-1 11.88±13.28 0.00±0.00 0.014*
p53i 29.38±28.86 18.33±16.96 0.307
c-myc 30.63±24.07 16.11±20.28 0.141
bcl-2 1.88±7.50 6.67±5.00 0.003*
Table 1. EBER, LMP-1, EBNA-1, p53i, c-myc, and bcl-2 Expressions in both Infected and Non-infected OSCC
* significantly different if α<0.05
p53i bcl-2 c-myc
Molecules p-value B p-value B p-value B
EBER 0.155 0.282 0.761 0.021 0.215 0.297
LMP-1 0.387 0.237 0.260 0.108 0.891 0.045
EBNA-1 0.007* 1.043 0.230 0.151 0.994 0.03
Table 2. The Effects of EBV Virus Molecules (EBER, LMP-1, EBNA-1) on the Carcinogenesis Molecules 
(p53i, bcl-2, c-myc) 
*significantly affecting if P<0.05; B is regression coefficient
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with EBV, about 6.67.
Based on the results of the analysis above, 
the regression analysis then was performed to determine 
the effects of EBV infection on carcinogenesis. 
The results of the regression analysis indicated that only 
EBNA-1 induced p53i. Therefore, it can be assumed that 
EBV expression plays an important role in carnogenesis, 
but only EBNA-1 has direct effect. Meanwhile, EBER 
and LMP-1 are assumed to have no direct effect. This is 
supported by the opinion of Rowe and Rickinson (2001) 
that the expression of EBNA-1 is associated with certain 
types of tumors. Allegedly, one of them is oral carcinoma.
Moreover, since only EBNA-1 expression affected 
p53i expression in this research, EBNA-1 could be 
assumed to be able to make p53 expression inactive. 
The significant difference found between LMP-1 and 
EBER in both infected and noninfected groups indicates 
that LMP-1 and EBER have a role in carcinoma in 
the oral cavity. It is similar to previous study which 
showed that EBER and LMP-1 are found in almost 
all tumors (Rowe and Rickinson, 2001). LMP-1, 
according to MeckesRaab-Traub (2011), can even trigger 
the transformation of epithelial cells to be malignant by 
inhibiting cancer cell apoptosis. An important target of 
LMP-1 is mediated transcriptional upregulation of EGFR, 
a member of ErbB receptor tyrosine kinase family. EGFR 
is a growth factor receiver that activates multiple signaling 
pathways and often causes mutations to cause cancer.
Nevertheless, further researchers are still necessary to 
be conducted to determine the correlation of the molecular 
grading patterns and clinical staging in OSCC infected 
with EBV.
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